Sdamlo Solution
Product Images NDC 81279-133

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sdamlo (NDC 81279-133). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pangea Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle 10mg (Bottle 10mg)

This text provides information on a medication called Sdamlo (amlodipine) for oral solution. The product contains 10 mg of amlodipine provided as 13.88 mg amlodipine besylate. The dosage details are available in the prescribing information. It should be stored at 20°C to 25°C (68°F to 77°F) and the reconstituted content must be used immediately. Any unused content should be discarded after 60 minutes, and a new bottle should be used for the next dose. The medication is manufactured for Pangea Pharmaceuticals in Brielle, NJ.*

FDA Label Image

Bottle 2.5mg (Bottle 2.5mg)

FDA Label Image

Bottle 5mg (Bottle 5mg)

FDA Label Image

Carton 10mg (Carton 10mg)

FDA Label Image

Carton 2.5mg (Carton 2.5mg)

FDA Label Image

Carton 5mg (Carton 5mg)

FDA Label Image

Chemical Structure (Norliquid 01)

FDA Label Image

Figure 1 (Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine versus Placebo)

This text contains information about the event rate, Povalue, Flazars Rato, and confidence intervals. The Flazars Rato is reported as 0.691 with a 95% confidence interval of (0.54, 0.88). The data points mentioned are 130 e, S04 2, and at ek.*

FDA Label Image

Figure 2 – Effects On Primary Endpoint Of Amlodipine Versus Placebo Across Sub-groups (Norliquid 03)

This is a statistical evaluation of the effectiveness of Amlodopine compared to Placebo on various patient groups. It includes data on age, gender, baseline Sitting Systolic Blood Pressure (SBP), Baseline Vessel Disease presence, Baseline Vessels with Stenosis, and PCI-stent strategies. The Hazard Ratio and 95% Confidence Interval are provided for the comparison. The study involved 1318 patients, and specific subgroup analyses are also presented based on age, gender, baseline SBP, and vessel conditions.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.